Poolbeg Pharma (POLB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 7.60p
   
  • Change Today:
      0.000p
  • 52 Week High: 14.90
  • 52 Week Low: 7.40
  • Currency: UK Pounds
  • Shares Issued: 500.00m
  • Volume: 972,957
  • Market Cap: £38.00m
  • Beta: 0.78

Poolbeg Pharma Overview

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which the Directors believe enables it to develop multiple products faster and more cost effectively than the traditional biotech model. Poolbeg has aspirations to become the “one-stop shop” for Big Pharma seeking mid-stage products to license or acquire.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 2.6  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Poolbeg Pharma Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 n/a (2.34) (0.74)p n/a n/a n/a n/a 0.0%
31-Dec-22 n/a (4.78) (0.94)p n/a n/a n/a n/a 0.0%
31-Dec-23 n/a (4.51) (0.79)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Poolbeg Pharma Company Announcements

POLB 001 Patent Granted in United States 20-Nov-2024 07:00 RNS
Interim results for the six months to 30 June 2024 18-Sep-2024 07:00 RNS
Holding(s) in Company 12-Aug-2024 13:28 RNS

Poolbeg Pharma ShareCast News

Poolbeg Pharma granted new US patent 20-Nov-2024 ShareCast
Poolbeg agrees 12-month option over potential Be... 30-Apr-2024 ShareCast
Poolbeg Pharma to be granted US patent 20-Mar-2024 ShareCast

Latest Poolbeg Pharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

Poolbeg Pharma Market Data

Currency UK Pounds
Share Price 7.60p
Change Today 0.000p
% Change 0.00 %
52 Week High 14.90
52 Week Low 7.40
Volume 972,957
Shares Issued 500.00m
Market Cap £38.00m
Beta 0.78

Poolbeg Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
61.33% below the market average61.33% below the market average61.33% below the market average61.33% below the market average61.33% below the market average
36% below the sector average36% below the sector average36% below the sector average36% below the sector average36% below the sector average
Price Trend
55.9% below the market average55.9% below the market average55.9% below the market average55.9% below the market average55.9% below the market average
10.2% below the sector average10.2% below the sector average10.2% below the sector average10.2% below the sector average10.2% below the sector average
Income Not Available
Growth Not Available

Poolbeg Pharma Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
16:37 30,000 @ 7.60p
16:03 30,000 @ 7.60p
16:03 30,000 @ 7.60p
15:59 6,443 @ 7.76p
15:59 300 @ 7.75p

Poolbeg Pharma Key Personnel

CEO Jeremy Skillington
CFO Ian O’Connel

Top of Page